Mostrando 2 resultados de: 2
Filtros aplicados
Origen
scopus(2)
Nimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
ReviewAbstract: Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptorPalabras claves:eGFR, glioma, Humanized, Monoclonal antibody, nimotuzumab, Overall survival, SCCHNAutores:Arvind A., Eswaraiah A., Iyer H., Piedra-Sierra P., Ramakrishnan M., Saurez G., Tania CrombetFuentes:scopus